Acadia Pharmaceuticals Inc. (ACAD) said Wednesday that its Phase 3 COMPASS PWS study of carbetocin for the treatment of patients with hyperphagia or extreme hunger associated with Prader-Willi syndrome failed to meet its primary endpoint.
COMPASS PWS was a 12-week, randomized, placebo-controlled global Phase 3 trial evaluating the efficacy and safety of intranasal carbetocin in individuals aged 5 to 30 years with Prader-Willi syndrome (PWS), a rare genetic disorder. The trial found that intranasal carbetocin did not show a statistically significant improvement over placebo on the primary endpoint—the change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT), a caregiver-reported measure of food-seeking behaviors in individuals with PWS.
The safety and tolerability profile of intranasal carbetocin was consistent with previous trials, with a low rate of adverse events.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.